Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX
U.S. Clinical Sites Screening Treatment-Experienced Participants with Wet AMD
ODYSSEY Topline Results Expected in Q3 2024
ALPHARETTA, Ga., June 01, 2023 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that enrollment has opened in the ODYSSEY Phase 2b clinical trial of CLS-AX, an investigational axitinib injectable suspension, for the treatment of wet age-related macular degeneration (AMD) in treatment-experienced patients.
The ODYSSEY Phase 2b clinical trial is designed to evaluate the safety and efficacy of CLS-AX in patients who have previously been treated for wet AMD. The trial will be conducted at multiple clinical sites across the United States, with topline results expected in the third quarter of 2024.
Wet AMD is a leading cause of vision loss in older adults, affecting millions of people worldwide. Currently available treatments require frequent injections into the eye, which can be burdensome for patients. Clearside Biomedical’s SCS® technology aims to provide a more effective and convenient treatment option for patients with wet AMD.
By opening enrollment in the ODYSSEY Phase 2b clinical trial, Clearside Biomedical is taking a significant step towards advancing the development of CLS-AX and potentially improving outcomes for patients with wet AMD. The company’s innovative approach to drug delivery has the potential to revolutionize the treatment of retinal diseases and make a meaningful impact on the lives of patients.
How This Will Affect Me
As a patient with wet AMD or someone who knows someone with the condition, the opening of enrollment in the ODYSSEY Phase 2b clinical trial of CLS-AX represents a potential new treatment option that could offer improved outcomes and greater convenience compared to current therapies. By participating in the clinical trial, you may have the opportunity to access a cutting-edge therapy and contribute to the advancement of treatment options for wet AMD.
How This Will Affect the World
The development of CLS-AX and Clearside Biomedical’s SCS® technology has the potential to have a significant impact on the field of ophthalmology and the treatment of retinal diseases worldwide. By providing a more effective and convenient method of drug delivery, Clearside Biomedical is poised to improve outcomes for patients with wet AMD and potentially other retinal conditions in the future. The results of the ODYSSEY Phase 2b clinical trial could pave the way for a new era in the treatment of eye diseases and benefit patients around the world.
Conclusion
The enrollment opening in the ODYSSEY Phase 2b clinical trial of CLS-AX marks an important milestone in the development of innovative treatment options for wet AMD. Clearside Biomedical’s SCS® technology has the potential to revolutionize the delivery of therapies to the back of the eye, offering patients a more effective and convenient treatment option. The results of the clinical trial are eagerly anticipated, with the hope that they will lead to improved outcomes for patients with wet AMD and other retinal diseases.
